Peptide therapy TikTok claims: what the science actually supports

What did @charitykface actually say?

The creator recommended three peptides for a beginner who hasn't yet lost all their weight: a GLP-1 agonist, NAD+ (which they categorized as a "mitochondria repair" compound), and something they called "MOTC," which they described as helping with energy and workout endurance. They also advised against adding "leaning out peptides" until the person has lost most of their weight. The question came from a follower asking about starting points.

Fair warning before we go further: the transcript is phonetically garbled in places. "AD and MOTC" and "Chiz Appetide" don't correspond to any recognized peptide names. "MOTC" may be a mispronunciation of AOD-9604, a modified fragment of human growth hormone, or possibly MOTS-c, a mitochondria-derived peptide. This ambiguity matters, because these are very different compounds with different evidence profiles. We'll address both possibilities.

Does the science back this up?

The evidence varies dramatically across these three categories, and treating them as equivalent beginner picks is a stretch. GLP-1 receptor agonists have the strongest evidence base of any weight-related intervention in recent memory. NAD+ precursors have promising but still preliminary human data. MOTS-c and AOD-9604 are barely out of preclinical stages for most applications.

On GLP-1 agonists: semaglutide's STEP trials (Wilding et al., 2021, New England Journal of Medicine) showed an average 14.9% body weight reduction over 68 weeks in adults with obesity. That's a real signal. The creator isn't wrong to flag it as a reasonable starting point for someone trying to lose weight.

On NAD+: Yoshino et al. (2021, Science) found that NMN supplementation improved muscle insulin sensitivity in postmenopausal women, but the sample was small and the effects were modest. The "mitochondria repair" framing the creator uses is an oversimplification. NAD+ precursors support mitochondrial function, but calling it repair implies a therapeutic action the evidence doesn't yet confirm in healthy adults.

On MOTS-c specifically: Lee et al. (2015, Cell Metabolism) identified MOTS-c as a mitochondrial-derived peptide that improved insulin sensitivity and reduced obesity in mice. Human data is essentially nonexistent at this point. If that's what the creator meant, recommending it to beginners is premature.

What did they get wrong (or right)?

Credit where it's due: the GLP-1 recommendation for someone with significant weight to lose is defensible. The advice to hold off on body composition peptides like GHK-Cu or CJC-1295 until weight loss is established also reflects reasonable clinical logic. Stacking aggressive compounds on a metabolically stressed body is not a great idea.

What they got wrong, or at least muddied: the transcript conflates NAD+ (a coenzyme precursor, not technically a peptide) with peptide therapy. NAD+ is not a peptide. Including it in a peptide stack list without clarifying that distinction misleads viewers about what they're actually taking and how these compounds work. The creator says "NAD or MOTC" as if these are interchangeable, and they are not remotely interchangeable. One has meaningful human trial data; the other barely has mouse data.

The energy and workout claims attached to "MOTC" are also unsubstantiated for human use. Promising animal data is not clinical evidence. Presenting it as a practical beginner option without that caveat is irresponsible.

What should you actually know?

If you're considering any of these compounds, here's what the evidence actually supports versus what is still speculative. GLP-1 receptor agonists are the only category here with robust, peer-reviewed, large-scale human trial data for weight management. They are also FDA-regulated prescription medications. You cannot legally obtain them without a licensed prescriber.

NAD+ precursors like NMN and NR have early human evidence for metabolic support but nothing close to confirmed therapeutic benefit in otherwise healthy people. They are sold as supplements, not medications, which means quality control varies significantly.

MOTS-c, if that's what the creator meant, is a research peptide. It has no FDA approval for any indication. No established dosing exists for humans. No large-scale safety data exists. Recommending it as a "top 3 beginner" compound without those caveats is a significant omission.

Finally: the creator frames these as a personal list, not medical advice, which is appropriate. But framing matters less when 9,600 people are watching and taking notes. Anyone considering peptide therapy should be working with a licensed provider who can assess their individual health status, not building a stack from TikTok comments.